At the PAN Foundation Cost-Sharing Roundtable, a variety of voices were represented from across healthcare to discuss the importance of the safety net, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.
At the PAN Foundation Cost-Sharing Roundtable, a variety of voices were represented from across healthcare to discuss the importance of the safety net, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.
Transcript
What was a key takeaway from the discussions at the PAN Foundation Cost-Sharing Roundtable?
The roundtable was really pretty energizing, because I think we saw a lot of different perspectives being represented from the payer community, from the pharma community, from the patient advocacy community, from the patient assistance community. And I think my takeaway was that there are some opportunities for common understanding and broadly supported strategies.
I think everybody recognizes that paying for value-based care will free up critical dollars to be used more efficiently to provide patient assistance and I think everybody also came away understanding that the need for a safety net is probably growing. As the patients age, as we go from 57 million patients in Medicare to 70 million plus, it's likely that there's going to be a continuing need for patient assistance, for safety net programs. So it's key that we all work together across our different areas of expertise to make that as efficient as possible, to make sure that it reaches the people who need it, and that everyone can get access to the care they need.
So the roundtable, hopefully, gave everybody a good boost of energy to go back to their offices, to their jobs, to their careers, to their constituents and help move us forward in terms of strenthening and sustaining the safety net.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More